| First Author | McClatchy J | Year | 2023 |
| Journal | Nat Commun | Volume | 14 |
| Issue | 1 | Pages | 8102 |
| PubMed ID | 38062031 | Mgi Jnum | J:343480 |
| Mgi Id | MGI:7564833 | Doi | 10.1038/s41467-023-43697-y |
| Citation | McClatchy J, et al. (2023) Clonal hematopoiesis related TET2 loss-of-function impedes IL1beta-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells. Nat Commun 14(1):8102 |
| abstractText | Clonal hematopoiesis (CH) is defined as a single hematopoietic stem/progenitor cell (HSPC) gaining selective advantage over a broader range of HSPCs. When linked to somatic mutations in myeloid malignancy-associated genes, such as TET2-mediated clonal hematopoiesis of indeterminate potential or CHIP, it represents increased risk for hematological malignancies and cardiovascular disease. IL1beta is elevated in patients with CHIP, however, its effect is not well understood. Here we show that IL1beta promotes expansion of pro-inflammatory monocytes/macrophages, coinciding with a failure in the demethylation of lymphoid and erythroid lineage associated enhancers and transcription factor binding sites, in a mouse model of CHIP with hematopoietic-cell-specific deletion of Tet2. DNA-methylation is significantly lost in wild type HSPCs upon IL1beta administration, which is resisted by Tet2-deficient HSPCs, and thus IL1beta enhances the self-renewing ability of Tet2-deficient HSPCs by upregulating genes associated with self-renewal and by resisting demethylation of transcription factor binding sites related to terminal differentiation. Using aged mouse models and human progenitors, we demonstrate that targeting IL1 signaling could represent an early intervention strategy in preleukemic disorders. In summary, our results show that Tet2 is an important mediator of an IL1beta-promoted epigenetic program to maintain the fine balance between self-renewal and lineage differentiation during hematopoiesis. |
